The use of herbal medicine in cancer-related Anorexia/ Cachexia treatment around the world

Current Pharmaceutical Design

Volumn 18, Issue 31, 2012, Pages 4819-4826

  Cheng, Kai Chun ^a   Li, Ying Xiao ^a   Cheng, Juei Tang ^b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Cancer cachexia treatment; Cancer related cachexia; Chinese herbs; Food intake; Insulin resistance; Proinflammatory cytokines

Indexed keywords

BU ZHONG YI QI TANG; CANNABINOID; CHINESE DRUG; ESSIAC; HERBACEOUS AGENT; KAMPO; PHY 906; RADIXIN; RHYO JEN ZHU TANG; RIKKUNSHITO; SHI QUAN DA BU TANG; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT;

ANOREXIA; ARTICLE; CACHEXIA; CANCER PATIENT; CANCER THERAPY; GASTROINTESTINAL TOXICITY; GINSENG; HERBAL MEDICINE; HUMAN; NONHUMAN; NUTRITION; PRIORITY JOURNAL; RADIX ASTRAGALI; RHIZOME; RHUBARB; TRADITIONAL MEDICINE;

ANIMALS; ANOREXIA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APPETITE STIMULANTS; CACHEXIA; DIETARY SUPPLEMENTS; GASTROINTESTINAL AGENTS; HUMANS; MEDICINE, TRADITIONAL; NEOPLASMS; PLANT PREPARATIONS; WORLD HEALTH;

EID: 84866360607     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803216979     Document Type: Article

References (112)

1. Bozzetti F, on behalf of the SCRINIO Working Group. Screening the nutritional status in oncology: a preliminary report on 1, 000 outpatients. Support Care Cancer 2009; 17: 279-284
2. Tan BHL, Fearon KCH. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008; 11: 400-407.
3. Drinan L. Cancer cachexia. Nurs Stand 2011 Oct 12-18; 26: 59.
4. Fearon KCH, Voss AC, Halstead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake and systemic inflammation on functional status and prognosis. Am J Clin Nutr 2006; 83: 1345-1350.
5. Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clin Nutr 2008; 27: 793-799
6. Lindsey AM, Piper BF. Anorexia and weight loss: indicators of cachexia in small cell lung cancer. Nutr Cancer 1985; 7: 65-76.
7. Tisdale MJ. Cancer cachexia: metabolic alterations and clinical manifestations. Nutrition 1997; 13: 1-7.
8. Devereux DF, Redgrave TG, Tilton M, Hollander D, Deckers PJ. Intolerance to administered lipids in tumor-bearing animals. Surgery 1984; 96: 414-419.
9. Vlassara H, Spiegel RJ, San Doval D, Cerami A. Reduced plasma lipoprotein lipase activity in patients with malignancy-associated weight loss. Horm Metab Res 1986; 18: 698-703.
10. Mantovani G, Macciò A, Massa E, Madeddu C. Managing cancerrelated anorexia/cachexia. Drugs 2001; 61: 499-514.
11. Ramos EJ, Suzuki S, Marks D, Inui A, Asakawa A, Meguid MM. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 2004; 7: 427-434.
12. Ramos EJ, Suzuki S, Marks D, Inui A, Asakawa A, Meguid MM. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 2004; 7(4): 427-434.
13. Katafuchi T, Motomura K, Baba S, et al. Differential effects of tumor necrosis factor-a and -b on rat ventromedial hypothalamic neurons in vitro. Am J Physiol 1997; 272: 1966-1971.
14. Torelli GF, Meguid MM, Moldawer LL, et al. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol Regul Integr Comp Physiol 1999; 277: R850-R855.
15. Argiles JM, Moore-Carrasco R, Busquets S, Lopez-Soriano FJ. Catabolic mediators as targets for cancer cachexia. Drug Disc Today 2003; 8: 838-844.
16. Turrin NP, Ilyn SE, Gayle D, et al. Interleukin-1b system in anorectic catabolic tumor bearing rats. Cytokine, Neuropeptide and G Protein alpha-subunit mRNAs in Anorectic MCA Tumor Bearing Rats. Curr Opin Clin Nutr 2004; 4: 419-426.
17. Plata-Salaman CR. Immunoregulators in the nervous system. Neurosci Biobehav Rev 1991; 15: 185-215.
18. Yang ZJ, Blaha V, Meguid MM, et al. Interleukin-1alpha injection into ventromedial hypothalamic nucleus of normal rats depresses food intake and increases release of dopamine and serotonin. Pharmacol Biochem Behav 1999; 62: 61-65.
19. Martin F, Santolaria F, Batista N, et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999; 11: 80-86.
20. Maltoni M, Fabbri L, Nanni O, et al. Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 1997; 5: 130-135.
21. Gold J. Cancer cachexia and gluconeogenesis. Ann N Y Acad Sci 1974; 230: 103-110.
22. Lundholm K, Edström S, Karlberg I, Ekman L, Scherstén T. Glucose turnover, gluconeogenesis from glycerol and estimation of net glucose cycling in cancer patients. Cancer 1982; 50: 1142-1150.
23. Lynch N, Berry D. Differences in perceived risks and benefits of herbal, over-the-counter conventional, and prescribed conventional, medicines, and the implications of this for the safe and effective use of herbal products. Complement Ther Med 2007; 15: 84-91.
24. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004; 22: 2489-2503.
25. Wells M, Sarna L, Cooley ME, et al. Use of complementary and alternative medicine therapies to control symptoms in women living with lung cancer. Cancer Nurs 2007; 30: 45-55.
26. Yang C, Chien LY, Tai CJ. Use of complementary and alternative medicine among patients with cancer receiving outpatient chemotherapy in Taiwan. J Altern Complement Med 2008; 14: 413-416.
27. Molassiotis A, Fernandez-Ortega P, Pud D, et al. Complementary and alternative medicine use in colorectal cancer patients in seven European countries. Complement Ther Med 2005; 13: 251-257.
28. Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol. A meta-analysis. Ann Intern Med 1993; 119: 599-605.
29. Werneke U, Earl J, Seydel C, Horn O, Crichton P, Fannon D. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004; 90: 408-413.
30. MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med 2002; 35: 166-173.
31. Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs 2005; 65: 1239-1282.
32. Izzo AA. Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 2005; 19: 1-16.
33. Ross WE. Unconventional cancer therapy. Compr Ther 1985; 11: 37-43
34. Unconventional Cancer Treatments September 1990 OTA-H-405 NTIS order #PB91-104893
35. Olsnes S, Stirpe F, Sandvig K, Pihl A. Isolation and characterization of viscumin, a toxic lectin from Viscum album L. (mistletoe). J Biol Chem 1982; 257: 13263-13270.
36. Holtskog R, Sandvig K, Olsnes S. Characterization of a toxic lectin in Iscador, a mistletoe preparation with alleged cancerostatic properties. Oncology 1988; 45: 172-179.
37. Kuttan G, Vasudevan DM, Kuttan R. Isolation and identification of a tumour reducing component from mistletoe extract (Iscador). Cancer Lett 1988; 41: 307-314.
38. Jordan E, Wagner H. Structure and properties of polysaccharides from Viscum album (L.). Oncology 1986; 1: 8-15.
39. Coeugniet EG, Elek E. Immunomodulation with Viscum album and Echinacea purpurea extracts. Onkologie 1987; 10: 27-33.
40. Hajto T. Immunomodulatory effects of iscador: a Viscum album preparation. Oncology 1986; 43: 51-65.
41. Gold J. Cancer cachexia and gluconeogenesis. Ann N Y Acad Sci 1974; 230: 103-110.
42. Khwaja TA, Dias CB, Pentecost S. Recent studies on the anticancer activities of mistletoe (Viscum album) and its alkaloids. Oncology 1986; 43: 42-50.
43. Mistletoe extracts (PDQ): Overview. NCA Web site, [Accessed 8/22/04].
44. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 2002; 52: 72-91.
45. Fainsinger R. Pharmacological approach to cancer anorexia and cachexia. In: Bruera E, Higginson I, Eds. Cachexia-anorexia in cancer patients. Oxford, England: Oxford University Press 1996; pp. 128-140.
46. Gorter RW. Cancer cachexia and cannabinoids. Forsch Komplementarmed 1999; 3: 21-22.
47. Argilés JM, Meijsing SH, Pallarés-Trujillo J, Guirao X, López- Soriano FJ. Cancer cachexia: a therapeutic approach. Med Res Rev 2001; 21: 83-101.
48. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
49. Regelson W, Butler JR, Schultz J: Delta-9-tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: Braude MC, Szara S, Eds. The Pharmacology of Marijuana. New York: Raven Press 1976; pp. 763-776.
50. Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9- tetrahydrocannabinol for appetite stimulation in cancerassociated anorexia. J Palliat Care 1994; 10: 14-18.
51. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40: 695-700.
52. Wadleigh R, Spaulding GM, Lumbersky B. Dronabinol enhancement of appetite in cancer patients. Proc Am Soc Oncol 1990; 9: 331.
53. Plasse TF, Gorter RW, Krasnow SH: Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40: 695-700.
54. Chinese Herbals Editor Board, the State Administrative Bureau of Chinese Medicine of China, Chinese Herbals (Zhong Hua Ben Cao). Shanghai: Shanghai Science and Technology Press 1999; pp.213-223 (Chinese).
55. Liao HM, Yang YQ, Bai JL. A survey of therapeutic and adjunctional effects of Chinese medicines on tumours. Xi Zang Ke Ji 2003; 8: 42-43 (Chinese).
56. Efferth T, Miyachi H, Bartsch H. Pharmacogenomics of a traditional Japanese herbal medicine (Kampo) for cancer therapy. Cancer Genomics Proteomics 2007; 4: 81-91
57. Hsu HY. Treating Cancer with Chinese Herbs. Los Angeles: Oriental Healing Arts Institute, 1982.
58. Qi F, Li A, Inagaki Y, et al. Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends 2010; 4: 297-307.
59. Qi F, Li A, Inagaki Y, et al. Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends 2010; 4: 297-307.
60. Hofseth LJ, Wargovich MJ. Inflammation, cancer, and targets of ginseng. J Nutr 2007; 137: 183-185.
61. Lee TK, Johnke RM, Allison RR, O'Brien KF, Dobbs LJ Jr. Radioprotective potential of ginseng. Mutagenesis 2005; 20: 237-243.
62. Yun TK, Choi SY. Preventive effect of ginseng intake against various human cancers: A case-control study on 1,987 pairs. Cancer Epidemiol Biomarkers Prev 1995; 4: 401-408.
63. Iizuka N, Miyamoto K, Okita K, et al. Inhibitory effect of Coptidis rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Lett 2000; 148: 19-25.
64. Fukutake M, Yokota S, Kawamura H, et al. Inhibitory effect of Coptidis rhizoma and Scutellariae radix on azoxymethane-induced aberrant crypt foci formation in rat colon. Biol Pharm Bull 1998; 21: 814-817.
65. Li XK, Motwani M, Tong W, Bornmann W, Schwartz GK. Huanglian, a Chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells. Mol Pharmacol 2000; 58: 1287-1293.
66. Ozaki Y, Suzuki H, Satake M. [Comparative studies on concentration of berberine in plasma after oral administration of coptidis rhizome extract, its cultured cells extract, and combined use of these extracts and glycyrrhizae radix extract in rats]. Yakugaku Zasshi 1993; 113: 63-69.
67. Chi CW, Chang YF, Chao TW, et al. Flowcytometric analysis of the effect of berberine on the expression of glucocorticoid receptors in human hepatoma HepG2 cells. Life Sci 1994; 54: 2099-2107.
68. Kuo CL, Chou CC, Yung BY. Berberine complexes with DNA in the berberine-induced apoptosis in human leukemic HL-60 cells. Cancer Lett 1995; 93: 193-200.
69. Wu HL, Hsu CY, Liu WH, Yung BY. Berberine-induced apoptosis of human leukemia HL-60 cells is associated with down-regulation of nucleophosmin/B23 and telomerase activity. Int J Cancer 1999; 81: 923-929.
70. Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol 2009; 126: 5-17.
71. Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992; 89: 1681-1684.
72. Kurebayashi J, Yamamoto S, Otsuki T, Sonoo H. Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect. Br J Cancer 1999; 79: 631-636.
73. Ebisui C, Tsujinaka T, Morimoto T, et al. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2C12 myotubes. Clin Sci (Lond).1995; 89: 431-439.
74. Cahlin C, Korner A, Axelsson H, Wang W, Lundholm K, Svanberg E. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 2000; 60: 5488-5493.
75. Fujiki F, Mukaida N, Hirose K, et al. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res 1997; 57: 94-99.
76. Lorite MJ, Cariuk P, Tisdale MJ. Induction of muscle protein degradation by a tumour factor. Br J Cancer 1997; 76: 1035-1040.
77. Tohda C, Nakayama N, Hatanaka F, Komatsu K. Comparison of Anti-inflammatory Activities of Six Curcuma Rhizomes: A Possible Curcuminoid-independent Pathway Mediated by Curcuma phaeocaulis Extract. Evid Based Complement Alternat Med 2006; 3: 255-260.
78. Iizuka N, Hazama S, Yoshimura K, et al. Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma. Int J Cancer 2002; 99: 286-291.
79. Jiao Y, Wen J, Yu X. Influence of flavonoid of Astragalus membranaceus's stem and leaves on the function of cell mediated immunity in mice. Zhongguo Zhong Xi Yi Jie He Za Zhi 1999; 19: 356-358.
80. Chu DT, Lin JR, Wong W. The in vitro potentiation of LAK cell cytotoxicity in cancer and aids patients induced by F3--a fractionated extract of Astragalus membranaceus. Zhonghua Zhong Liu Za Zhi 1994; 16: 167-171.
81. Yoshida Y, Wang MQ, Liu JN, Shan BE, Yamashita U. Immunomodulating activity of Chinese medicinal herbs and Oldenlandia diffusa in particular. Int J Immunopharmacol 1997; 19: 359-370.
82. Lee JJ, Lee JJ. A phase II study of an herbal decoction that includes Astragali radix for cancer-associated anorexia in patients with advanced cancer. Integr Cancer Ther 2010; 9: 24-31.
83. Wang S, Penchala S, Prabhu S, Wang J, Huang Y. Molecular basis of traditional Chinese medicine in cancer chemoprevention. Curr Drug Discov Technol 2010; 7: 67-75.
84. Saiki I. A Kampo medicine Juzen-taiho-to - prevention of malignant progression and metastasis of tumor cells and the mechanism of action. Biol Pharm Bull 2000; 23: 677-688.
85. Niwa K, Hashimoto M, Morishita S, et al. Preventive effects of Juzen-taiho-to on N-methyl-N-nitrosourea and estradiol-17betainduced endometrial carcinogenesis in mice. Carcinogenesis 2001; 22: 587-591.
86. Kamiyama H, Takano S, Ishikawa E, Tsuboi K, Matsumura A. Anti-angiogenic and immunomodulatory effect of the herbal medicine "Juzen-taiho-to" on malignant glioma. Biol Pharm Bull 2005; 28: 2111-2116.
87. Hamada M, Fujii Y, Yamamoto H, et al. Effect of a kanpo medicine, zyuzentaihoto, on the immune reactivity of tumor-bearing mice. J Ethnopharmacol 1988; 24(2/3): 311-320.
88. Yang AK, He SM, Liu L, Liu JP, Wei MQ, Zhou SF. Herbal interactions with anticancer drugs: Mechanistic and clinical considerations. Curr Med Chem 2010; 17: 1635-1678.
89. Zhu K, Fukasawa I, Furuno M, et al. Inhibitory effects of herbal drugs on the growth of human ovarian cancer cell lines through the induction of apoptosis. Gynecol Oncol 2005; 97: 405-409.
90. Kao ST, Yeh CC, Hsieh CC, et al. The Chinese medicine Bu- Zhong-Yi-Qi-Tang inhibited proliferation of hepatoma cell lines by inducing apoptosis via G0/G1 arrest. Life Sci 2001; 69: 1485-1496.
91. Li T, Tamada K, Abe K, et al. The restoration of the antitumor T cell response from stress-induced suppression using a traditional Chinese herbal medicine Hochu-ekki-to (TJ-41: Bu-Zhong-Yi-Qi- Tang). Immunopharmacology 1999; 43: 11-21.
92. Kim SH, Lee SE, Oh H, et al. The radioprotective effects of buzhong-yi-qi-tang: A prescription of traditional Chinese medicine. Am J Chin Med 2002; 30: 127-137.
93. Jeong JS, Ryu BH, Kim JS, Park JW, Choi WC, Yoon SW. Bojungikki-tang for cancer-related fatigue: A pilot randomized clinical trial. Integr Cancer Ther 2010; 9: 331-338.
94. Lam W, Bussom S, Guan F, et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med 2010; 2: 45-59.
95. Saif MW, Lansigan F, Ruta S, et al. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine 2010; 17: 161-169.
96. Yen Y, So S, Rose M, et al. Phase I/II study of PHY906/ capecitabine in advanced hepatocellular carcinoma. Anticancer Res 2009; 29: 4083-4092.
97. Farrell MP, Kummar S. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2003; 2: 253-256.
98. Kerem M, Ferahkose Z, Yilmaz UT, et al. Adipokines and ghrelinin gastric cancer cachexia. World J Gastroenterol 2008; 21: 3633-3641.
99. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomised, placebo-con-trolled trial. J Clin Endocrinol Metab 2004; 89: 2832-2836.
100. Tack J, Depoortere I, Bisschops R, et al. Infl uence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 2006; 55: 327-333.
101. Matsumura T, Arai M, Yonemitsu Y, et al. The traditional Japanese medicine Rikkunshito increases the plasma level of ghrelin in humans and mice. J Gastroenterol 2010; 45: 300-307.
102. Takeda H, Sadakane C, Hattori T, et al. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology 2008; 134: 2004-2013.
103. Fujitsuka N, Asakawa A, Hayashi M, et al. Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin. Biol Psychiatry 2009; 65: 748-759.
104. Ohno T, Kamiyama Y, Aihara R, et al. Ghrelin does not stimulate gastrointestinal motility and gastric emptying: an experimental study of conscious dogs. Neurogastroenterol Motil 2006; 18: 129-135.
105. Matsumura T, Arai M, Yonemitsu Y, et al. The traditional Japanese medicine Rikkunshito increases the plasma level of ghrelin in humans and mice. J Gastroenterol 2010; 45: 300-307.
106. De Vry J, Schreiber R. Effects of selected serotonin 5-HT1 and 5- HT2 receptor agonists on feeding behavior: possible mechanisms of action. Neurosci Biobehav Rev 2000; 24: 341-353.
107. Takeda H, Sadakane C, Hattori T, et al. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology 2008; 134: 2004-2013.
108. Mochiki E, Yanai M, Ohno T, Kuwano H. The effect of traditional Japanese medicine (Kampo) on gastrointestinal function. Surg Today 2010; 40: 1105-1111.
109. Tatsuta M, Iishi H. Effect of treatment with liu-jun-zi-tang (TJ-43) on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment Pharmacol Ther 1993; 7: 459-462.
110. Tominaga K, Kido T, Ochi M, et al. The traditional Japanese medicine Rikkunshito promotes gastric emptying via the antagonistic action of the 5-HT3 receptor pathway in rats. Evid Based Complement Alternat Med 2011; 20111: 248481.
111. Hayakawa T, Arakawa T, Kase Y, et al. Liu-Jun-Zi-Tang, a kampo medicine, promotes adaptive relaxation in isolated guinea pig stomachs. Drugs Exp Clin Res 1999; 25: 211-218.
112. Shiratori M, Shoji T, Kanazawa M, Hongo M, Fukudo S. Effect of rikkunshito on gastric sensorimotor function under distention. Neurogastroenterol Motil 2011; 23: 323-329.